Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

NCT03294083 is registered in ClinicalTrials.gov with SillaJen, Inc. as lead sponsor.

NCT NCT03294083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03294083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)
Lead sponsor
SillaJen, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 19, 2018
Completion date
February 16, 2023
Enrollment
95 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma